Alnylam Pharma (ALNY) Tops Q3 EPS by 15c, Misses on Revenue, Offers FY22 Revenue Guidance
Go back to Alnylam Pharma (ALNY) Tops Q3 EPS by 15c, Misses on Revenue, Offers FY22 Revenue Guidance| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 286.41 +8.32 (2.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $278.09 | 52 Week High | $109.10 | |||
| Open | $278.42 | 52 Week Low | $31.38 | |||
| Day High | $286.67 | P/E | N/A | |||
| Day Low | $278.17 | EPS | $-1.45 | |||
| Volume | 1,420,698 | |||||
